CFM
ELDN icon

Catalyst Funds Management’s Eledon Pharmaceuticals ELDN Stock Holding History

Catalyst Funds Management’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,400
Closed -$29.5K – 402
2025
Q3 		$29.5K Buy
+11,400
New +$33.3K ﹤0.01% 479
2025
Q2 		– Sell
-13,620
Closed -$46.2K – 518
2025
Q1 		$46.2K Buy
+13,620
New +$56K 0.01% 416

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
ZP
Zimmer Partners New York $4.15B AUM 14.2% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Catalyst Funds Management's ELDN Position: Q4 2025 in Review

Catalyst Funds Management sold out of Eledon Pharmaceuticals (ELDN) in Q4 2025, closing a stake of 11,400 shares — an estimated $29.5K sold.

Catalyst Funds Management first reported a position in ELDN in Q1 2025 and held it in 2 quarters. The position peaked at $46.2K in Q1 2025. 95 funds tracked by Wall St. Rank hold ELDN as of Q4 2025.

  • Catalyst Funds Management reported no remaining Eledon Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Catalyst Funds Management sold 11,400 Eledon Pharmaceuticals shares in Q4 2025, an estimated $29.5K.
  • Catalyst Funds Management first reported a position in Eledon Pharmaceuticals in Q1 2025 and held it in 2 quarters.
  • Catalyst Funds Management's Eledon Pharmaceuticals position peaked at $46.2K in Q1 2025.
  • 95 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q4 2025.

Based on Catalyst Funds Management's 13F filing for Q4 2025, filed 9 Feb 2026.